Effectiveness of switching from nalfurafine to difelikefalin in patients with hemodialysis-associated pruritus: a prospective interventional study within a new treatment algorithm
Abstract Background Since June 2009, our facility has been using an internally developed treatment algorithm that facilitates a comprehensive approach to address each cause of hemodialysis-associated pruritus (HAP), wherein oral nalfurafine, a selective κ-opioid receptor (KOR) agonist, is used for p...
Saved in:
| Main Authors: | Naoko Takahashi, Taku Yoshizawa, Junko Kumagai, Hideki Kawanishi, Shinichiro Tsuchiya, Misaki Moriishi, Takao Masaki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Renal Replacement Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41100-025-00653-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis
by: Xiaoyue Cai, et al.
Published: (2024-12-01) -
The efficacy and safety of difelikefalin for pruritus in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials
by: Abdallah Saeed, et al.
Published: (2024-12-01) -
Contrasting Evolution After Withdrawal of Long-Term Administration of Difelikefalin for CKD-Associated Pruritus
by: Guy Rostoker, et al.
Published: (2024-04-01) -
Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study
by: Linda H. Ficociello, et al.
Published: (2025-03-01) -
Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients
by: Ping Zhang, et al.
Published: (2023-12-01)